GlassScriptPhysician profile
Gbenga Aluko
NPI 1437102753
$5,941.96
in general payments reported to CMS, 2019-2025
26 companies · $544 in 2025
The $544 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,781 · 2020: $540 · 2021: $841 · 2022: $703 · 2023: $778 · 2024: $756 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,066 · Education: $10.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,066.28 |
| Education | $10.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,617.45 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $1,064.95 | 2019-2023 | Xarelto |
| Pfizer INC. | $574.25 | 2019-2025 | |
| Novo Nordisk INC | $442.85 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $417.41 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.85 | 2019-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $237.46 | 2019-2022 | |
| Amgen INC. | $235.78 | 2024-2025 | Krystexxa |
| Horizon Therapeutics Plc | $162.63 | 2023 | Krystexxa |
| Abbvie INC. | $146.62 | 2022-2024 | Qulipta, Ubrelvy |
| Vertex Pharmaceuticals Incorporated | $140.12 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.03 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $121.83 | 2023 | Onpattro |
| Davol INC. | $92.38 | 2025 | Phasix Mesh |
| Merck Sharp & Dohme LLC | $55.69 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $41.22 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $37.84 | 2021-2022 | |
| Astellas Pharma Global Development | $34.81 | 2023 | Veozah |
| Mylan Specialty L.P. | $30.87 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $22.74 | 2024 | Zoryve |
| Amarin Pharma, INC. | $19.23 | 2019 | |
| Fidia Pharma USA INC. | $17.74 | 2019 | |
| Medline Industries LP | $16.28 | 2020 | |
| Bioventus LLC | $16.02 | 2019 | |
| Glaxosmithkline, LLC. | $13.78 | 2019 | |
| Phadia US INC. | $13.13 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gbenga Aluko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.